Ticker Details
Evolus, Inc. Evolus Inc is engaged in providing physicians and their patients with expanded choices in medical aesthetic treatments and procedures. Its product candidate is an injectable formulation of a 900 kDa Botulinum toxin Type A complex.
IPO Date:	February 5, 2018
Sector:	Healthcare
Industry:	Drug Manufacturers
Market Cap:	$275.85M
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$0.35 | 3.08%
Avg Daily Range (30 D):	$0.11 | 2.41%
Avg Daily Range (90 D):	$0.12 | 2.33%

Institutional Daily Volume
Avg Daily Volume:	.64M
Avg Daily Volume (30 D):	1.21M
Avg Daily Volume (90 D):	1.01M

Trade Size
Avg Trade Size (Sh.):	109
Avg Trade Size (Sh.) (30 D):	96
Avg Trade Size (Sh.) (90 D):	94

Institutional Trades
Total Institutional Trades:	1,050
Avg Institutional Trade:	$1.36M
Avg Institutional Trade (30 D):	$1.1M
Avg Institutional Trade (90 D):	$1.08M
Avg Institutional Trade Volume:	.12M
Avg Institutional Trades (Per Day):	1

Market Closing Trades
Avg Closing Trade:	$1.14M
Avg Closing Trade (30 D):	$1.68M
Avg Closing Trade (90 D):	$1.15M
Avg Closing Volume:	102.19K

News

Dec 28, 2025 @ 5:26 PM ANI Stock Is Up 49% This Past Year, Revenue Is Sur... Source: Jonathan Ponciano

Dec 19, 2025 @ 11:00 PM AEON Biopharma Reports Inducement Grants Under NYS... Source: Aeon Biopharma, Inc.

Mar 10, 2025 @ 8:53 PM Mixue Group's Splashy Debut, Kroger's Change, Stuf... Source: Dylan Lewis

Jun 6, 2024 @ 12:00 PM Rare Stock Picks In May 2024 - From 29 Discerning ... Source: SA Rare Stock Picks Monthly

May 21, 2024 @ 2:57 PM Evolus (EOLS) Releases Favorable Dermal Fillers St... Source: Zacks Equity Research

Financials
	TTM	Q4 2025	FY 2025
Basic EPS	$-.8	$	$-.8
Diluted EPS	$-.8	$	$-.8
Revenue	$297.18M	$90.3M	$297.18M
Gross Profit	$197.11M	$59.29M	$197.11M
Net Income / Loss	$-51.64M	$.13M	$-51.64M
Operating Income / Loss	$-32.66M	$4.22M	$-32.66M
Cost of Revenue	$100.07M	$31.01M	$100.07M
Net Cash Flow	$-33.13M	$10.3M	$-33.13M
PE Ratio